2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Leukemia
53
Lymphoma
51
Melanoma
44
Breast Neoplasms
37
Lymphoma, Follicular
36
Leukemia, Myeloid, Acute
33
Leukemia, Lymphocytic, Chronic, B-Cell
30
Precursor Cell Lymphoblastic Leukemia-Lymphoma
29
Lymphoma, Non-Hodgkin
29
Neuroblastoma
28
Multiple Myeloma
28
Lymphoma, Large B-Cell, Diffuse
25
Prostatic Neoplasms
24
Lymphoma, Mantle-Cell
23
Myelodysplastic Syndromes
22
Lymphoma, Large-Cell, Immunoblastic
20
Neoplasms, Plasma Cell
19
Leukemia, Myeloid, Chronic-Phase
19
Lung Neoplasms
18
Hodgkin Disease
18
Carcinoma, Non-Small-Cell Lung
18
Burkitt Lymphoma
18
Ovarian Neoplasms
17
Lymphoma, B-Cell, Marginal Zone
17
Neoplasm Metastasis
16
Glioblastoma
16
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
15
Congenital Abnormalities
15
Leukemia, Myeloid, Accelerated Phase
14
Colorectal Neoplasms
13
Interventions
pembrolizumab
14
Injections
13
Paclitaxel
10
Nivolumab
10
Docetaxel
9
Cisplatin
9
Capecitabine
9
Bevacizumab
8
toripalimab
7
senaparib
7
Fluorodeoxyglucose F18
7
Cyclophosphamide
7
tislelizumab
6
atezolizumab
6
Irinotecan
6
Fluorouracil
6
Gemcitabine
5
fludarabine
4
apatinib
4
Oxaliplatin
4
Leucovorin
4
Ipilimumab
4
Carboplatin
4
spartalizumab
3
sintilimab
3
pertuzumab
3
olaparib
3
camrelizumab
3
Rifampin
3
Radiosurgery
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Solid Tumor
×
sargramostim
×
Clear all
NCT05284214
2023-09-15
SALIENT
Partner Therapeutics, Inc.
Phase 2
Withdrawn